PT - JOURNAL ARTICLE AU - Lake, Douglas F. AU - Roeder, Alexa J. AU - Kaleta, Erin AU - Jasbi, Paniz AU - Pfeffer, Kirsten AU - Koelbel, Calvin AU - Periasamy, Sivakumar AU - Kuzmina, Natalia AU - Bukreyev, Alexander AU - Grys, Thomas E. AU - Wu, Liang AU - Mills, John R AU - McAulay, Kathrine AU - Gonzalez-Moa, Maria AU - Seit-Nebi, Alim AU - Svarovsky, Sergei TI - Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2 AID - 10.1101/2020.12.15.20248264 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.15.20248264 4099 - http://medrxiv.org/content/early/2021/11/03/2020.12.15.20248264.short 4100 - http://medrxiv.org/content/early/2021/11/03/2020.12.15.20248264.full AB - Background After receiving a COVID-19 vaccine, most recipients want to know if they are protected from infection and for how long. Since neutralizing antibodies are a correlate of protection, we developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies from a drop of blood. The LFA is based on the principle that neutralizing antibodies block binding of the receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2).Methods The ability of the LFA was assessed to correctly measure neutralization of sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2 microneutralization assays. We also determined if the LFA distinguished patients with seasonal respiratory viruses from patients with COVID-19. To demonstrate the usefulness of the LFA, we tested previously infected and non-infected COVID-19 vaccine recipients at baseline and after first and second vaccine doses.Results The LFA compared favorably with SARS-CoV-2 microneutralization assays with an area under the ROC curve of 98%. Sera obtained from patients with seasonal coronaviruses did not show neutralizing activity in the LFA. After a single mRNA vaccine dose, 87% of previously infected individuals demonstrated high levels of neutralizing antibodies. However, if individuals were not previously infected only 24% demonstrated high levels of neutralizing antibodies after one vaccine dose. A second dose boosted neutralizing antibody levels just 8% higher in previously infected individuals, but over 63% higher in non-infected individuals.Conclusions A rapid, semi-quantitative, highly portable and inexpensive neutralizing antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing antibodies to COVID-19.Competing Interest StatementAJR, EK, PJ, SP, NK, AB, TG, LW, JRM and KM have no competing interests. DFL received support from Axim Biotechnologies to perform the study. SS and AS-N are supported and employed by Axim Biotechnologies.Funding StatementAxim Biotechnologies supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peripheral blood and serum were collected for this study under an Arizona State University IRB approved protocol #0601000548 and Mayo Clinic IRB protocol #20-004544.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is available.